Premium
Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab
Author(s) -
Almadori Giovanni,
Lauriola Libero,
Coli Antonella,
Bussu Francesco,
Gallus Roberto,
Scan Domenico,
Valentini Vincenzo,
Paludetti Gaetano,
Carey Thomas E.,
Ranelletti Franco O.
Publication year - 2017
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24670
Subject(s) - cetuximab , immunohistochemistry , oncology , radiation therapy , minichromosome maintenance , medicine , cancer research , tumor progression , head and neck squamous cell carcinoma , biology , head and neck cancer , cancer , colorectal cancer , proliferating cell nuclear antigen , eukaryotic dna replication
Background Minichromosome maintenance protein 7 (MCM7) is a downstream of human epidermal growth receptor (HER1) signaling. We examined MCM7, geminin, and HER1 expression in patients with laryngeal squamous cell carcinoma (SCC) treated with radiotherapy and cetuximab. Methods MCM7, geminin, and HER1 were evaluated by immunohistochemistry on 61 patients with laryngeal SCC. The follow‐up (median, 32.1 months; range, 2–139 months) went from the beginning of therapy to tumor progression‐free survival (PFS) and death (overall survival [OS]). Results MCM7, but not geminin, was associated only with HER1 expression, whereas no association was found with other clinicopathological characteristics. Patients with MCM7 high ‐ geminin high and MCM7 high ‐ geminin low tumor status had a risk of progression 3.1 times and 17.7 times greater, respectively, than patients with MCM7 low – geminin high tumor status. Tumor site, MCM7, and geminin were independent determinants of PFS, whereas MCM7 was an independent prognostic marker of OS. Conclusion MCM7‐geminin tumor status may be prognostic for patients with laryngeal SCC treated with cetuximab and radiotherapy. © 2016 Wiley Periodicals, Inc. Head Neck 39: 684–693, 2017